Shenzhen Salubris Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Shenzhen Salubris Pharmaceuticals has a total shareholder equity of CN¥8.6B and total debt of CN¥60.0M, which brings its debt-to-equity ratio to 0.7%. Its total assets and total liabilities are CN¥10.2B and CN¥1.6B respectively. Shenzhen Salubris Pharmaceuticals's EBIT is CN¥594.0M making its interest coverage ratio -10. It has cash and short-term investments of CN¥1.9B.
Key information
0.7%
Debt to equity ratio
CN¥60.00m
Debt
| Interest coverage ratio | -10x |
| Cash | CN¥1.91b |
| Equity | CN¥8.64b |
| Total liabilities | CN¥1.59b |
| Total assets | CN¥10.23b |
Recent financial health updates
These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely
Nov 11
Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?
Feb 28Recent updates
Is Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) Trading At A 29% Discount?
Dec 18Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Could Signal Some Risk
Nov 29These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely
Nov 11We Think That There Are More Issues For Shenzhen Salubris Pharmaceuticals (SZSE:002294) Than Just Sluggish Earnings
Sep 02What Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Not Telling You
Aug 23Are Investors Undervaluing Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) By 21%?
Aug 02Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Share Price Not Quite Adding Up
May 22A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)
Apr 17Is Shenzhen Salubris Pharmaceuticals (SZSE:002294) A Risky Investment?
Feb 28Financial Position Analysis
Short Term Liabilities: 002294's short term assets (CN¥3.8B) exceed its short term liabilities (CN¥1.0B).
Long Term Liabilities: 002294's short term assets (CN¥3.8B) exceed its long term liabilities (CN¥576.9M).
Debt to Equity History and Analysis
Debt Level: 002294 has more cash than its total debt.
Reducing Debt: 002294's debt to equity ratio has reduced from 5.4% to 0.7% over the past 5 years.
Debt Coverage: 002294's debt is well covered by operating cash flow (1930.7%).
Interest Coverage: 002294 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen Salubris Pharmaceuticals Co., Ltd. is covered by 23 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| Peng Yan | Changjiang Securities Co. LTD. |
| Liehai Xu | China Merchants Securities Co. Ltd. |